Drug Profile
Research programme: graft-versus-host disease therapeutics - Mallinckrodt/Keio University
Alternative Names: GvHD therapeutics - Mallinckrodt/Keio UniversityLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator R-Tech Ueno
- Developer Keio University School of Medicine; Mallinckrodt plc
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry eyes; Graft-versus-host disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Dry-eyes in Japan
- 28 Jul 2018 No recent reports of development identified for research development in Graft-versus-host-disease in Japan
- 13 Feb 2018 Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc